Free Trial

Eterna Therapeutics Q2 2024 Earnings Report

Eterna Therapeutics logo
$0.25 +0.00 (+1.05%)
(As of 12/20/2024 05:31 PM ET)

Eterna Therapeutics Earnings Headlines

Eterna Therapeutics Inc Ordinary Shares
Eterna launches research to evaluate ERNA-101
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna regains compliance with Nasdaq
See More Eterna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eterna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eterna Therapeutics and other key companies, straight to your email.

About Eterna Therapeutics

Eterna Therapeutics (NASDAQ:ERNA), a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Eterna Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings